<DOC>
	<DOCNO>NCT02617810</DOCNO>
	<brief_summary>The purpose study evaluate effect multiple-dose administration JNJ-42847922 single-dose pharmacokinetics oral midazolam single-dose pharmacokinetics pharmacodynamics ( R ) - ( S ) -warfarin oral administration racemic warfarin .</brief_summary>
	<brief_title>A Study Assess Effect Multiple-Dose Administration JNJ-42847922 Midazolam Warfarin Healthy Participants</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , single-center , fixed-sequence , study JNJ-42847922 healthy participant . The study consist 3 Phases : Screening Phase ( 28 Days ) , open-label treatment Phase ( 40 Days ) follow visit ( 7 14 Days last study procedure ) . The duration participation study participant approximately 82 Days . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Signed informed consent document indicate understand purpose procedure require study willing participate study Willing adhere prohibition restriction specify protocol If woman , must childbearing potential : postmenopausal [ great equal ( &gt; = ) 45 year age amenorrhea least 2 year , age amenorrhea least 6 month serum stimulate hormone ( FSH ) great ( &gt; ) 40 International unit per liter ( IU/L ) , surgically sterile ( example , hysterectomy , oophorectomy , tubal ligation tubal occlusion ) If woman , must agree donate egg ( ovum , oocytes ) purpose assist reproduction least 3 month last dose study drug If man sexually active woman childbearing potential vasectomy , must agree use adequate contraception method deem appropriate Investigator ( example , vasectomy , doublebarrier , partner use effective contraception ) donate sperm study 3 month receive last dose study drug Body mass index ( BMI ) 18 30 kilogram ( kg ) /meter^2 ( m^2 ) , body weight less 50 kg History current clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , syncope , hypotension , hypertension vascular disorder , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , hepatic renal insufficiency , kidney urinary tract disturbance , thyroid disease , neurologic disease , significant psychiatric disorder , epilepsy , fit unexplained blackout , infection , illness Investigator considers exclude participant could interfere interpretation study result Clinically significant abnormal value hematology , clinical chemistry , urinalysis , thyroid stimulate hormone ( TSH ) Screening Day 1 first treatment period deem appropriate Investigator . In addition , participant must coagulation test result [ ( prothrombin time ( PT ) , international normalize ratio ( INR ) , activate partial thromboplastin time ( aPTT ) ] within clinically acceptable limit Screening deemed appropriate Investigator Clinically significant abnormal physical examination , vital sign , 12 lead electrocardiogram ( ECG ) Screening Day 1 first treatment period deem appropriate Investigator Participants homozygous heterozygous CYP2C9*2 CYP2C9*3 allele Use prescription nonprescription medication ( include vitamin herbal supplement ) , except acetaminophen , within 14 day first dose study drug schedule completion study . In addition , participant exclude used medication know affect coagulation modulate CYP2C9 VKORC1 within 28 day study admission</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Healthy</keyword>
	<keyword>JNJ-42847922</keyword>
	<keyword>Midazolam</keyword>
	<keyword>Warfarin</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>